Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Место клопидогреля в лечении больных с атеротромботической болезнью согласно современным рекомендациям
Место клопидогреля в лечении больных с атеротромботической болезнью согласно современным рекомендациям
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В статье рассматриваются вопросы, связанные с профилактикой осложнений атеротромбоза посредством антиагрегационной терапии. Представлены доказательства целесообразности применения клопидогреля как монопрепарата антиагрегационной направленности, так и в комбинации с ацетилсалициловой кислотой в предупреждении атеротромботических осложнений. Обсуждаются основные положения и современные рекомендации разных международных сообществ, касающиеся показаний к назначению клопидогреля, его нагрузочных и поддерживающих доз, а также длительности приема в разных клинических ситуациях.
Ключевые слова: атеротромбоз, ишемическая болезнь сердца, баллонная ангиопластика, стентирование, клопидогрель.
Key words: atherothrombosis, ischemic heart disease, balloon angioplasty, stenting, clopidogrel.
Ключевые слова: атеротромбоз, ишемическая болезнь сердца, баллонная ангиопластика, стентирование, клопидогрель.
________________________________________________
Key words: atherothrombosis, ischemic heart disease, balloon angioplasty, stenting, clopidogrel.
Полный текст
Список литературы
1. Бокерия Л.А., Гудкова Р.Г. Сердечно-сосудистая хирургия. НЦССХ им. А.Н.Бакулева РАМН. М., 2010.
2. Панченко Е.П. Атеротромбоз: механизмы развития и реально проводимая терапия. Атеротромбоз. 2008; 1: 22–6.
3. Munger MA, Hawkins DW. Atherothrombosis: epidemiology, pathophysiology, and prevention. J Am Pharm Assoc 2004; 44 (Suppl. 1): S5–S12.
4. Fuster V, Moreno PR, Fayad ZA et al. Atherothrombosis and high-risk plaque. I. Evolving concepts. J Am Coll Cardiol 2005; 46: 937–54.
5. Kannel WB. Risk factors for atherosclerotic cardiovascular outcomes in different arterial territories. J Cardiovasc Risk 1994; 1: 333–9.
6. Blatt DL, Steg PG, Ohman EM et al International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295: 180–9.
7. Albers GW, Amarenco P, Easton JD et al. Antithrombotic and thrombolytic therapy for ischemic stroke (the 7th ACCP Conference on antithrombotic and thrombolytic therapy). Chest 2004; 126 (Suppl. 3): 483S–512S.
8. Преображенский Д.В., Сидоренко Б.А, Батыралиев Т.А. и др. Тиенопиридины в лечении и профилактике сердечно-сосудистых заболеваний. Часть II. Клиническая фармакология клопидогрела. Кардиология 2009; 10: 88–96.
9. Aleil B, Ravanat C, Cazenave JP et al. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005; 3: 85–92.
10. Law WC, Gurbek PA, Watkins PB et al. Contribution to hepatic cytochrome P450 3A4 metabolic activity to the phenomen of clopidogrel. Circulation 2004; 109: 166–71.
11. Snoep JD, Hovens MM, Eikenboom JC et al. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: systemic review and meta-analysis. Am Heart J 2007; 154: 221–31.
12. Tentzeris I, Siller-Matula J, Farhan S et al. Platelet function variability and non-genetic causes. Thrombosis and Haemostasis 2011; 11, www.thrombosis-online.com
13. CAPRIE Steering Committee. A randomized, blinded, trial of Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE). Lancet 1996; 348: 1329–39.
14. Bhatt DL, Fox KA, Hacke W et al for the CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706–17.
15. Markus HS, Droste DW, Kaps M et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stanosis evaluated using Doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in symptomatic carotid Stenosis (CARESS) trial. Circulation 2005; 111: 2233–40.
16. Smith SD, Benjamin EJ, Bonow RO et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011; 124. Published Online.
17. Yusuf S, Zhao F, Mehta SR et al. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. NEJM 2001; 345: 494–502.
18. Mehta SR, Bassand JP, Chrolavicius S et al. CURRENT-OASIS 7 Investigators. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl Med 2010; 363: 930–42.
19. Sabatine MS, Cannon CP, Gibson CM et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. NEJM 2005; 352: 1179–89.
20. Hamm CW et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. ESC Guidelines. Eur Heart J 2011, Published Online.
21. Van de Werf F et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. Eur Heart J 2008; 29: 2909–45.
22. Kushner FG et al. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update). J Am Coll Cardiol 2009; 54: 2205–41.
23. Cook S, Ladich E, Nakazawa G et al. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation 2009; 120: 391–9.
24. Steinhubl SR, Berger PB, Mann JT et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 222: 2411–20.
25. Montalescot G, Sideris G, Meuleman C et al. A randomized comparison of high clopidogrel loading dose in patients with non-ST-segment elevation acute coronary syndromes. The ALBION (Assessment of the best Loading dose of clopidogrel to Blunt platelet activation, Inflammation and Omgoing Necrosis) trail. JACC 2006; 48: 931–8.
26. Angioillo D, Fernandez-Oritz A, Bernardo E. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur Yeart J 2004; 25: 1903–10.
27. Aleil B, Jacquemin L, De Poli F et al. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phospoprotein-02) Randomized Study. JACC Cardiovasc Interv 2008; 1: 631–8.
28. Sikker-Matuka JM, Huber R, Chirst G et al. Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systemic review and meta-analysis. Heart 2011; 97: 98–105.
29. Wijns W, Kolh P, Danchin N et al. Guidelines on myocardial revascularization. ESC/EACTS Guidelines. Eur Heart J 2010; 31: 2501–55.
30. Levine GN et al. ACC/AHA/SCAI Guidelines for Percutaneous Coronary Intervention. JACC 2011; 58 (24). Published Online.
2. Панченко Е.П. Атеротромбоз: механизмы развития и реально проводимая терапия. Атеротромбоз. 2008; 1: 22–6.
3. Munger MA, Hawkins DW. Atherothrombosis: epidemiology, pathophysiology, and prevention. J Am Pharm Assoc 2004; 44 (Suppl. 1): S5–S12.
4. Fuster V, Moreno PR, Fayad ZA et al. Atherothrombosis and high-risk plaque. I. Evolving concepts. J Am Coll Cardiol 2005; 46: 937–54.
5. Kannel WB. Risk factors for atherosclerotic cardiovascular outcomes in different arterial territories. J Cardiovasc Risk 1994; 1: 333–9.
6. Blatt DL, Steg PG, Ohman EM et al International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295: 180–9.
7. Albers GW, Amarenco P, Easton JD et al. Antithrombotic and thrombolytic therapy for ischemic stroke (the 7th ACCP Conference on antithrombotic and thrombolytic therapy). Chest 2004; 126 (Suppl. 3): 483S–512S.
8. Преображенский Д.В., Сидоренко Б.А, Батыралиев Т.А. и др. Тиенопиридины в лечении и профилактике сердечно-сосудистых заболеваний. Часть II. Клиническая фармакология клопидогрела. Кардиология 2009; 10: 88–96.
9. Aleil B, Ravanat C, Cazenave JP et al. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005; 3: 85–92.
10. Law WC, Gurbek PA, Watkins PB et al. Contribution to hepatic cytochrome P450 3A4 metabolic activity to the phenomen of clopidogrel. Circulation 2004; 109: 166–71.
11. Snoep JD, Hovens MM, Eikenboom JC et al. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: systemic review and meta-analysis. Am Heart J 2007; 154: 221–31.
12. Tentzeris I, Siller-Matula J, Farhan S et al. Platelet function variability and non-genetic causes. Thrombosis and Haemostasis 2011; 11, www.thrombosis-online.com
13. CAPRIE Steering Committee. A randomized, blinded, trial of Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE). Lancet 1996; 348: 1329–39.
14. Bhatt DL, Fox KA, Hacke W et al for the CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706–17.
15. Markus HS, Droste DW, Kaps M et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stanosis evaluated using Doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in symptomatic carotid Stenosis (CARESS) trial. Circulation 2005; 111: 2233–40.
16. Smith SD, Benjamin EJ, Bonow RO et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011; 124. Published Online.
17. Yusuf S, Zhao F, Mehta SR et al. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. NEJM 2001; 345: 494–502.
18. Mehta SR, Bassand JP, Chrolavicius S et al. CURRENT-OASIS 7 Investigators. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl Med 2010; 363: 930–42.
19. Sabatine MS, Cannon CP, Gibson CM et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. NEJM 2005; 352: 1179–89.
20. Hamm CW et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. ESC Guidelines. Eur Heart J 2011, Published Online.
21. Van de Werf F et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. Eur Heart J 2008; 29: 2909–45.
22. Kushner FG et al. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update). J Am Coll Cardiol 2009; 54: 2205–41.
23. Cook S, Ladich E, Nakazawa G et al. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation 2009; 120: 391–9.
24. Steinhubl SR, Berger PB, Mann JT et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 222: 2411–20.
25. Montalescot G, Sideris G, Meuleman C et al. A randomized comparison of high clopidogrel loading dose in patients with non-ST-segment elevation acute coronary syndromes. The ALBION (Assessment of the best Loading dose of clopidogrel to Blunt platelet activation, Inflammation and Omgoing Necrosis) trail. JACC 2006; 48: 931–8.
26. Angioillo D, Fernandez-Oritz A, Bernardo E. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur Yeart J 2004; 25: 1903–10.
27. Aleil B, Jacquemin L, De Poli F et al. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phospoprotein-02) Randomized Study. JACC Cardiovasc Interv 2008; 1: 631–8.
28. Sikker-Matuka JM, Huber R, Chirst G et al. Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systemic review and meta-analysis. Heart 2011; 97: 98–105.
29. Wijns W, Kolh P, Danchin N et al. Guidelines on myocardial revascularization. ESC/EACTS Guidelines. Eur Heart J 2010; 31: 2501–55.
30. Levine GN et al. ACC/AHA/SCAI Guidelines for Percutaneous Coronary Intervention. JACC 2011; 58 (24). Published Online.
Авторы
М.Г.Бубнова
ФГБУ Государственный научно-исследовательский центр профилактической медицины Минздравсоцразвития РФ, Москва
mbubnova@gnicpm.ru
State Research Center for Preventive Medicine of the Ministry of Health of the Russian Federation, Moscow
mbubnova@gnicpm.ru
ФГБУ Государственный научно-исследовательский центр профилактической медицины Минздравсоцразвития РФ, Москва
mbubnova@gnicpm.ru
________________________________________________
State Research Center for Preventive Medicine of the Ministry of Health of the Russian Federation, Moscow
mbubnova@gnicpm.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.